By showing this, the Austrian Biotech is the first company* to succeed in controlling all the relevant immune checkpoints that prevent the immune system from attacking and defeating cancer.
Whereas current passive checkpoint specific immunotherapy lacks tumor cell specificity with the risk of massive autoimmune reactions, this new active therapy is totally tumor target specific.
Geert Mudde, PhD, inventor of the S-TIR™ technology and OncoQR ML’s Chief Scientific Officer, said, "We are proud and excited to have finally demonstrated the ability to activate and use the full potential of the patient’s own immune system to eradicate cancer. Previously, we had already shown all forms of antibody mediated tumor killing - now we have the definite proof that our S-TIR™ vaccines are able to simultaneously induce and activate tumor specific T Cell killing as well. With our approach, the tumor has no more chance to escape the immune system – it is attacked from all possible sides at the same time.”
Christof Langer, Chief Executive Officer of OncoQR ML, said, "These spectacular results confirm the viability and huge potential of our proprietary S-TIR™ platform. Besides constituting a significant milestone in the development of our immunotherapy platform technology, to our knowledge, no other anti-cancer drug has shown comparable results so far. The new data are not only spectacular from a scientific point of view: The S-TIR technology will also break the trend that new cancer therapies have to be unethically expensive. Our therapeutic vaccines are designed to have low cost of goods which is paired with a personalized low treatment frequency at low treatment dose. Drugs based on our technology can be used as monotherapy but can also be combined with existing therapies (like chemotherapy). Therefore, all in all, ground-breaking news for patients, and healthcare organizations, but of course also for us and our future partners.”
With the achievement of this ultimate scientific proof, OncoQR ML’s S-TIR™ technology has now moved into the direct focus of different investors, and potential licensing and development partners: “Our Active Checkpoint Control Immunotherapy (ACCI) is available for out-licensing either as a whole or on a targetby-target basis. Developing S-TIR™ based vaccines for new cancer targets up to in vivo proof-ofconcept typically only takes 6 to 9 months. Business partners, that are interested in truly enhancing the value of their current cancer immunotherapy product pipeline are warmly invited to contact us for additional information. This is not just another checkpoint inhibitor – it is a new, ground-breaking universal therapeutic approach.”
OncoQR ML´s cancer vaccines are based on the unique, proprietary, two-module S-TIR™ (Specific Total Immune Remodeler) platform. The vaccines are composed of a proprietary “generic” module (“warhead”) and a proprietary, disease-specific module (“immunogen”), linked by high-affinity connectors. In short, the warhead ensures specific delivery of the immunogen in a non-toxic manner to those cells that adjust and (re-)direct the patient’s immune response (i.e. dendritic cells and B-cells). In addition, the warhead not only strongly boosts but also determines the therapeutic effect of the drug. The modular concept facilitates the simple combination of the warhead with different immunogens, resulting in multi-purpose cancer immunotherapies.
About OncoQR ML GmbH
Privately held OncoQR ML GmbH, based in Vienna/Austria, is a pre-clinical biotech company that offers novel therapeutic cancer vaccines based on its unique, proprietary and broadly applicable S-TIR™ technology platform. Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific, and controlled immune response against cancer without triggering side effects. This “Active Checkpoint Control Immunotherapy” (ACCI) is capable of activating all four available and evolutionary perfected tumor killing mechanisms in parallel. The company’s first product TYG100 (formerly OQR100), in development by TYG Oncology Ltd. and CRUK, targets pancreatic and other gastrointestinal cancers by inducing neutralizing antibodies against little gastrin (G17), a major growth factor for these forms of cancer. OQR200 is directed against HER2/neu over-expressing breast cancer and induces strong polyclonal humoral and cellular (CD4 and CD8) immune responses, superior to trastuzumab, pertuzumab or passive checkpoint inhibitors. Both products as well as the S-TIR™ technology platform are available for partnering. For further information visit www.oncoqr.com and for specifics concerning TYG100 www.tyg-oncology.com
#Active therapy (protein/peptide based)
#No side effects
#Activation of all 4 naturally available killing mechanisms of the immune system
#Multiple cancer targets
Forward Looking Statements
Statements in this press release that are not purely historical are forward-looking statements. Forwardlooking statements herein include statements regarding OncoQR ML’s efforts to develop and commercialize S-TIR™ and related technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release. The forward-looking statements contained herein are made only as of the date of this press release and OncoQR ML undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
*) according to currently available public knowledge